Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: Pros and cons

Clinical Infectious Diseases

Volumn 29, Issue 3, 1999, Pages 503-507

  Feld, Ronald ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; CLAVULANIC ACID; TICARCILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CANCER; FEBRILE NEUTROPENIA; GRAM POSITIVE BACTERIUM; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW;

EID: 0032847254     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598622     Document Type: Review

References (22)

1. Wade JC, Schimpff SC, Newman KA, Wiernik PH. Staphylococcus epidermidis: an increased cause of infection in patients with granulocytopenia. Ann Intern Med 1982;96:503-8.
2. EORTC International Antimicrobial Therapy Cooperative Group, Gram-positive bacteraemia in granulocytopenic cancer patients. Eur J Cancer 1990;26:569-74.
3. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992;14:1201-7.
4. Elting LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247-59.
5. Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. Medicine 1984;63: 189-200.
6. Dompeling EC, Donnelly JP, Deresinski SC, Feld R, Lane-Allman EF, De Pauw BE. Early identification of neutropenic patients at risk of gram-positive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer 1996;32A:1332-9.
7. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-73.
8. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Reduction of fever and Streptococcus bacteraemia in granulocytopenic patients with cancer, A trial of oral penicillin vs. a placebo combined with pefloxacin. JAMA 1994;272:1183-9.
9. Bow EJ, Mandel LA, Louie TJ, et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. Ann Intern Med 1996;125: 183-90.
10. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-5.
11. Shenep JL, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988;319:1053-8.
12. EORTC International Antimicrobial Therapy Cooperative Group, National Cancer Institute of Canada Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-8.
13. Ramphal R, Bolger M, Oblon DJ, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 1992;36:1062-7.
14. Pico JL, Marie JP, Chiche D, et al. Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial. Eur J Med 1993;2:275-80.
15. Hughes WT, Armstrong D, Bodey GP, et al. From the Infectious Diseases Society of America: guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161: 381-96.
16. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicentcr randomized trial. Ann Intern Med 1994;120:834-44.
17. Wade JJ. Enterococcus faecium in hospitals. Eur J Clin Microbiol Infect Dis 1997;16:113-9.
18. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-53.
19. Suppola JP, Volin L, Valtonen VV, Vaara M. Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies. Clin Infect Dis 1996,23:694-7.
20. Henning KJ, Delencastre H, Eagan J, et al. Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996;15:845-7.
21. Philpott NJ, Brownlec R, Morrison D, et al. Vancomycin-resistant enterococci (VRE) on a leukemia/BMT unit [abstract no, 0335]. Bone Marrow Transplant 1997;19(suppl I):S84.
22. Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC), MMWR Morb Mortal Wkly Rep 1994;44:1-13.